Skip to main content
. 2021 Dec 2;16(12):e0259301. doi: 10.1371/journal.pone.0259301

Fig 4. CD8 T cells are critical for IL12 mediated tumor elimination.

Fig 4

(A) Mice inoculated subcutaneously with B16 melanoma tumors in their right flanks (n = 8–9) were depleted of one or (B) two critical immune populations using antibodies against CD8α, CD4 or NK1.1 (to deplete CD8 T cells, CD4 T cells or natural killer cells, respectively) throughout the experiment (n = 5–10). Mice were then given a single intratumoral injection of ILV/mIL12 on Day 7 and tumor growth was monitored. Survival benefit was determined using Mantel-Cox Log-rank testing where p < 0.05 is considered significant (*p = 0.002, **p = 0.0001). (C) Mice were inoculated with subcutaneous B16 melanoma tumors in their right flanks and then received one shot of ILV/mIL12 (n = 5). Tumors were isolated 7 days after ILV administration and infiltrating immune cells were isolated and phenotyped by flow cytometry analysis. Numbers in each square represent the percentage stained cells of live cells found in TIL population.